Abstract: Lung cancer is the leading cause of death from cancer in the world. Although the molecular network of lung carcinogenesis has been partly known at the levels of genes and proteins, and personalized therapy based on the genetic changes has made considerable progress in the last decade, the high mortality rate is not markedly changed. MicroRNAs (miRNAs), a class of short endogenous RNAs, acting as post-transcriptional regulators of gene expression, are similar with siRNAs in both the biosynthesis and the function steps. While, miRNAs mostly silence gene expression by binding imperfectly matched sequences in the 3 UTR of target mRNA, which is different with siRNAs by targeting ORF of mRNA with a perfectly complementary manner. miRNAs have multiple functions in lung development, and abnormal expression of miRNAs could lead to lung tumorigenesis. The different expression profiles of miRNAs in lung cancer, and the stability of miRNAs in serum, all together make them as new potentially clinical biomarkers for diagnosis and prognosis. Moreover, miRNAs may serve as either novel potential targets acting directly as oncogenes (e.g. miR-17-92 cluster) or directly therapeutic molecules working as tumor suppressor genes (e.g. let-7 family). RNAi technology based on miRNAs has many advantages over siRNAs, such as in vivo stability, highly RNA promoter-compatibility and no overt toxicity. Eventually, it might overcome the present disadvantages and become a good candidate for lung cancer therapy.
INTRODUCTION
Lung cancer is the leading cause of death from cancer in the world. Its pathogenesis is closely associated with tobacco smoking. Lung cancer is divided into two main histological groups including non-small cell lung cancer (NSCLC, 85%) and small cell lung cancer (SCLC, 15%). NSCLC can be further subclassified into adenocarcinomas, squamous cell, large cell and bronchoalveolar carcinomas (BAC). It is well known that genetic alterations could occur at the chromosomal level (e.g. large gains and deletions), at the nucleotide level (e.g. nucleotide mutation), or at epigenetic level (e.g. DNA methylation). Such a change could result in the activation of oncogenes (e.g. Ras, Myc) and other growth promoting genes (e.g. ERBB1, IGF-IR) , and the inactivation of tumor suppressor genes (e.g. p53, p16INK4A, Rb, FHIT). Ten or more genetic or epigenetic abnormalities are generally needed before lung tumor becomes clinically evident. The molecular network of lung carcinogenesis has been partly known at the levels of genes and proteins in the last decade (For reviews, see [1] [2] [3] ). However, since 1970 the high mortality rate (80-85% within 5 years) has not been markedly improved. The lack of effective tools to diagnose at an early stage and the deficiency of therapeutic treatments to the late stage of the disease are the two major reasons.
Currently available diagnostics for lung cancer, including chest imaging (X-ray or low-dose CT) and sputum cytology, often lack the sensitivity and specificity that are necessary to identify early stage disease. Only 16% of lung cancer is discovered prior to spread of the disease so far. Previous reports *Address correspondence to this author at the Institute of Molecular Medicine, Huaqiao University, 362021, China; Tel: 0086-0595-22690535; 0086-13905088091; Fax: 0086-0595-22690952; E-mail: ruianxu@hqu.edu.cn have shown that two blinded expert observers, when asked to give an independent histological classification of NSCLC, both agreed that the specificity of the disease was only 74.7 percent of the time, whereas sensitivity for squamous cell carcinoma is only 70.9 percent (For reviews, see [4] ). And even 40 percent of samples diagnosed as SCLC at regional labs were later reclassified as other lung cancer at central labs. Surgery only partly cured lung cancer patients at early stages [5] . Experimental treatment approaches, including small molecule targeted therapeutics, gene modified tumor vaccines, and viral-based gene therapy induced tumor regression, are still only used in a small proportion of patients. Currently, lung-cancer staging rests on histopathological and clinical criteria have only limited power to predict relapse and survival. A major effort to improve the control of lung cancer entails the use of molecular profiling to characterize tumors and to provide accurate predictions of the outcome after standard or novel treatments [6] .
MicroRNAs (miRNAs), a class of small, single-stranded endogenous RNAs, act as post-transcriptional regulators of gene expression. Some miRNAs may have as many as a few thousand targets, and that between 74% and 92% of the gene transcripts in four model genomes are likely under miRNA control. In general, the definition of miRNA requires mRNA that can be processed by Dicer (DCR) from the stem of a hairpin precursor to a～22-nt RNA [7] . The first miRNA, lin-4 was found in 1984 by Ambros and Horvitz [8] . While, the second 22-nt RNA gene let-7 was found until the year of 2000, after the discovery of the RNAi phenomenon [9] [10] [11] [12] . Until to Sept, 2008, the Sanger center in England had already contained 8619 entries representing hairpin precursor miRNAs (pre-miRNAs), expressing 8273 mature miRNA (matmiRNA) products in primates, rodents, birds, fishes, worms, flies, plants and viruses (http://microrna.sanger.ac.uk/).
In lung, expression patterns of miRNAs vary from fetal to adult, from normal to lung cancer. Specific miRNAs may have multi-functions in lung development and aberrant expression of miRNAs could induce lung tumorigenesis [13, 14] . The difference in expression of miRNAs between the normal lung and lung cancer leads to emerge as a novel type of biomarkers, which may not only helpful to diagnosis, but also could be novel therapeutic targets and good candidates for lung cancer therapy [15, 16] .
MECHANISM RELATIONSHIPS BETWEEN miRNAs AND siRNA
The phenomenon of RNAi was discovered in 1998 [12] . And now, both biochemical and genetic approaches have led to the current models of RNAi (For reviews, see [17] [18] [19] [20] ). RNAi is first initiated by dsRNAs, which are cleaved by the ribonuclease III-type enzyme DCR into siRNAs-short 21-23 nt duplexes with a symmetric 2 nt overhang at the 3'-end and a 5'-phosphate and 3'-hydroxy group. This siRNA molecule is incorporated into a nuclease-containing multi-protein complex called RNA-induced silencing complex (RISC). Then, RISC is activated by RNA helicase activity upon the loss of one strand of the siRNA duplex. In the effector steps, the single-stranded siRNA guides post-transcriptional gene silencing by degradation of their target mRNA (see Fig. 1 ).
In animal cells, miRNAs are first transcribed from genes by the RNA polymerase, most likely mediating by pol II [21, 22] (see Fig. 1 ). A majority of miRNA loci is found in intronic regions of protein-coding (intronic miRNAs), whereas the others are found in exonic regions of non-coding transcription units (exonic miRNAs) [23, 24] . MiRNA genes are transcribed to generate long primary transcripts (primiRNAs), then cleaved by RNase III enzyme (Drosha/ DGCR8) and/or spliceosomal components into hairpin-like pre-miRNAs in the nucleus [23] [24] [25] . The pre-miRNAs are transported into the cytoplasm with the help of a protein called Exportin 5, which is a member of the Ran-dependent nuclear transport receptor family [26] . In the cytoplasm, the pre-miRNAs are also cut into double stranded RNA duplexes by DCR [27] . Typically, one of the strands becomes matmiRNA (the other counterpart is named miRNA*) and is incorporated into a RISC with other components for target recognition [28] . The RISC then binds to its target mRNA through base pairing, and carries out its functions similar with siRNAs.
Many evidences point to a tight connection between miRNAs and siRNAs molecular machineries. The protein families that are most closely associated miRNAs with siRNAs are argonautes (AGOs) and DCR. The AGO1-4 is involved in miRNA biogenesis, while AGO2 is an essential component for siRNA-directed RNAi [29, 30] . Only one Fig. (1) . Connection between miRNAs and siRNAs molecular machineries. DCR enzyme is found in mouse and human, indicating that the same DCR serve for both miRNA-programmed RISC (miRISC) and siRNA-programmed RISC (siRISC). While, siRISC silences gene expression by cleaving a perfectly complementary target mRNA, and miRISC inhibits translation mostly by binding imperfectly matched sequences in the 3 UTR of target mRNA [31] . Regardless of the maturation process, once the small RNA is loaded, the RISC uses it to degrade or inhibit translation depending on the degree of complementarity between the small RNA and its mRNA target [29] . Components of the RNAi machinery, AGO1 and AGO2 are localized in mRNA processing bodies (P-bodies, also known as''cytoplasmic bodies'' and ''GW182 bodies'') that provide a possible linkage between siRNA-directed RNAi and miRNA-directed RNAi [32] [33] [34] [35] [36] [37] [38] [39] . Previous studies have also shown that miRNAs are crucial components in Pbodies formation, and the formation of P-bodies is a consequence of miRNA, but not the result of RNA-mediated gene silencing [40, 41] . Proteins that are involved in mRNA degradation, translational repression, mRNA surveillance and RNA-mediated gene silencing, together with their mRNA targets, colocalize within P-bodies [42] .
LUNG-SPECIFIC miRNAs
The expanding inventory of human miRNAs along with their highly diverse expression patterns and high number of potential target mRNAs suggest that miRNAs were involved in a wide variety of human organ development and diseases progress [43, 44] . For mammals, miRNAs are specifically expressed or greatly enriched in a particular organ such as lung, implying an organ-or tissue-specific function. First, it is found that lung is one of the tissues with the most abundant expression of let-7 [11] , which is reconfirmed by others [14, 45] . Then, six lung-specific miRNAs are identified in the adult mice by using northern analysis [46] . High throughput platforms further expand the lung-specific miRNAs [47, 48] . A rat miRNA microarray containing 216 miRNA probes revealed that two miRNAs were expressed specifically in rat lung and nine miRNAs co-expressed in lung and heart [47] .
The overall expression profile of miRNAs is similar in mouse and human lung [49, 50] , indicating evolutionary conservation of miRNA expression. Twenty-three of the 30 most highly expressed miRNAs shared in adult lungs from mice and human [49] . The miR -26, let-7, miR-29, miR-30 and miR-99 were expressed highly in both species. Similarly, miR -154, -134, -214, -296, -299, -323 , and -337 were highly expressed in both the neonatal mouse and the fetal human lung [49] . However, the expression of miRNAs in the postnatal and adult lung was different. When compared with mouse neonatal lung (1d) and the adult lung (60d), 14 miRNAs were highly expressed in the neonatal lung, while 30 miRNAs were up-regulated in adult lung. Similarly, 13 miRNAs were expressed more in human fetal lung than the adult lung, and 8 miRNAs were up-regulated in the adult lung. Most miRNAs that were highly expressed both in the neonatal mouse and the fetal human lung were subsequently down-regulated in the adult lung. In contrast, miRNAs such as miR-26b, -29a, -29b, -146-3p and -187 were up-regulated in the adult tissue of both mice and human. It was the same when compared E11.5 stage mouse lung with E17.5 lung. Although the 20 most abundant miRNAs were very similar, the amount of each miRNA varied significantly [13] . We have systematically analyzed above data, and found that miR -15, 126-3p, 30 and let-7 are up-regulated for both the E11.5 lung and the E17.5 lung, and for both the neonatal and the adult [13] (Table 1) . MiR-214 and miR-199 are both down-regulated in either mouse embryonic lung development process or human lung development from the neonatal to the adult lung [13, 49] . However, no significant changes are found for the expression of any individual miRNA in the aged lung (18 month) compared with the adult lung (6 month) [51] . The similar phenomenon also existed in the liver [52] . The dramatic change in miRNAs expression during embryonic and neonatal lung development indicates their crucial roles in these processes. NIH has therefore paid great attention to these molecules that may be of function in the embryonic and neonatal lung developmental process and lung tumorigenesis (http://researchresources. bumc.bu.edu /abstract/1R01HL081800-01A1.htm).
miRNA EXPRESSION PROFILE IN LUNG CANCER
Many studies have showed that miRNAs could mutate or poorly/over express in human cancer [53, 54] . Interestingly, miRNAs not only control the expression of known proteincoding oncogenes and tumor suppressors, but also act as oncogenes and tumor suppressors directly. It provides a high linkage between the altered expression of one or a few miRNAs and cancer development. Now, new clear evidences reveal that miRNA-expression profile of human tumors is closely associated with diagnosis, staging, progression, prognosis, and response to treatment [55] [56] [57] . A report named "micorRNA-based methods and compositions for the diagnosis and treatment of solid cancers" illustrated 123 miRNAs that may have potential roles in lung cancer (International publication number, WO2007/081740 A2). By comparing miRNA expression among lung cancer tissues versus the corresponding non-cancerous lung tissues, 43 miRNAs had statistical differences with 15 miRNAs upregulation ( Table 1 ). Volinia's studies also showed that 35 miRNAs were up-regulated, only 3 miRNAs were downregulated [53] . In contrast to these reports, Ambion demonstrated that three miRNAs were also expressed at significantly higher levels in the lung tumors, while six miRNAs were expressed at significantly lower levels (http://www.ambion.com/techlib/tn/121/4.html). Nevertheless, not so many miRNAs presented the same change pattern among these reports. It may be due to the different samples, the different technical platforms, or even to the different analytical methods. Peltier and Latham used stable pair of miRNAs to normalize different miRNAs expressed in Luca and normal samples [58] . They found that 7 miRNAs were up-regulated and 5 miRNAs were down-regulated in lung cancer (Table 1) . Again, these miRNAs are mostly different from the others [58] .
A number of dys-regulated miRNAs in lung cancer are located at the frequently deleted or amplified regions. For example, miR-21 and miR-205 are both located at the region amplified in lung cancer, whereas miR-126* and miR-126 are located at 9q34.3, a region deleted in lung cancer. These data are in agreement with the earlier reports that miRNA genes are frequently located at fragile sites (FRAs), as well as in minimal regions of loss of heterozygosity, minimal regions of amplification, or common breakpoint regions [59] [60] [61] .
Moreover, approximately 30% of the 43 miRNAs is located within exons or introns of known protein-coding genes [55] .
Indeed, the expression of many miRNAs are transcriptionally linked to the expression of other genes, coding for both proteins and noncoding RNAs [48, 62] . For example, the well-known miR-17-92 cluster resided in intron 3 of the C13orf25 gene at 13q31.3, within 800 base-pair region [60, 63] (See below for details).
miRNAs AS BIOMARKERS FOR LUNG CANCER DIAGNOSIS
The expression patterns of miRNAs between the normal lung and the cancer lung, the SCLC and the NSCLC, and the lung cancer and the other solid tumors, even other diseases are different. Such a difference not only exists in solid tumors, but also appears at plasma and serum of the patients. Particularly, serum miRNAs are resistant to RNase digestion, suggesting that miRNAs in serum are sufficiently stable to serve as clinical biomarkers [64] [65] [66] . These findings contribute to blood-based measurement of tumor-derived miRNAs as a potential new approach for the detection of human cancer. Twenty-eight miRNAs were missed and 63 new miRNAs were detected in the lung cancer serum when compared with the healthy subjects [65] . And 8 serum miRNAs were uniquely detected in lung cancer patients. Furthermore, the differential miRNA expression between serum and blood cells of lung cancer patients is a striking contrast to that of healthy subjects, in which serum and blood cells essentially share the same miRNA profile. Because miRNAs have some advantages over protein-based early-detection systems, including that they can be detected potentially in smaller quantities with a high throughput manner. Therefore, many companies, such as Rosetta Genomics Ltd., a famous company in the development of miRNA-based diagnostics, have paid great attention to the blood-based, non-invasive early detection. In 2006, Rosetta Genomics Ltd. announced to develop the technology for lung cancer together with U.S Genomics Inc. Their reports showed that miRNAs could be used as clinical biomarkers for a wide range of indications [66] . Mitchell et al. have shown serum levels of miR-141 can distinguish patients with prostate cancer from the healthy controls [64] . It is expected that these new biomarkers could be using in clinics successfully in near future.
Current diagnostics available for lung cancer often lack the sensitivity and specificity between NSCLC and SCLC and between adenocarcinoma and squamous cell carcinoma [4, 5] . The discovery of the new miRNA-based biomarkers may improve methodology for both sensitivity and specificity. It has been found that the expression of miR-29a, -29b, and -29c is down-regulated in NSCLCs [55, 67] . Six miRNAs were expressed differently in adenocarcinoma and squamous cell carcinoma, whereas six miRNAs shared both histological types of NSCLCs with higher expression levels of miR-99b and -102 in adenocarcinoma [55] . A decrease in precursor let-7a-2 and let-7f-1 expression was also found in adenocarcinoma and squamous cell carcinoma, respectively. These data strongly support miRNAs working as biomarkers for differentiating lung cancer. Although miRNAs have been identified as no different expression when classified by age, gender, or race [55] , their expression profiles in serum should be explored in more details. Recently, Rosetta Genomics Ltd, together with Columbia University Medical Center, has developed a cancer diagnostic test based on miRNA technology for differentiating squamous cell from non-squamous NSCLC. In their reports, miRNA signatures could classify squamous cell carcinoma of the lung at 90 percent of specificity and 96 percent of sensitivity. This is the first test utilizing miRNAs' unique sensitivity and specificity as biomarkers that may offer a standardized and objective method for cancer classification. Moreover, Lebanony et al. presented an abstract in 2008 ASCO Annual Meeting, showing that a single miRNA was sufficient to discriminate squamous cell carcinoma from other types of NSCLC. Studies also showed that miRNAs expression was very efficient to predict the histological classification between low and high grade lesions and between in situ and invasive squamous cell carcinoma [68] . In addition, miRNAs may also be powerful diagnostic tools for distinguishing difference between the primary lung tumors and lung metastases. For example, lung cancer shared a portion of its signature with breast cancer [53, 55] , but the loss of miR-335 and -126 expression was associated with poor distal lung metastasisfree survival in breast cancer [69] , and the suppression of miR-21 in metastatic breast cancer MDA-MB-231 cells significantly reduced invasion and lung metastasis [70] . Therefore, the lung cancer with low miR-335 and -126 levels and high miR-21 level may be metastasized from breast cancer.
CORRELATION BETWEEN miRNA AND LUNG CANCER SURVIVAL OUTCOME
The expression of individual miRNA and miRNA signatures has been linked to the prognosis of a number of human cancers. For lung cancer, firstly, it has been found that NSCLC had undergone potentially curative resection, which could be classified into two major groups according to let-7 expression levels [71] . A decrease in let-7 was associated with shortened postoperative survival and this prognostic impact was independent of disease stage, despite it was reported that reduction of let-7 expression was not correlated with the prognosis of BAC [72] . Secondly, eight miRNAs are found to be related to the patient's survival with the adenocarcinoma. Patients with high expression of miR-155, -17-3p, -106a, -93, -21 and low expression of let-7a-2, let-7b, miR-145 have had a significantly worse prognosis [55] . In particular, high miR-155 and low let-7a-2 expression appeared with poor survival. Yu et al. further identified a fivemiRNA signatures, including let-7a, miR-221, -137, -372, and -182*, were closely associated with survival and cancer relapse in NSCLC patients [73] . let-7a and miR-221 were protective and the other three miRNAs were risky. miR128b, a regulator of Egfr, its heterozygosity (LOH) was frequent in tumor samples and correlated significantly with clinical response and survival following gefitinib [74] . There is a strong correlation between miRNA expression and lung cancer patients' prognosis, suggesting that miRNAs may ultimately prove to be valuable cancer diagnostic and therapeutic analysis. Interestingly, most of protective miRNAs (e.g. let-7 family and miR-145) are down-regulated in lung cancer, while the risky miRNAs (e.g. miR-17-3p, -21, -93, -106a, and -155 ) are up-regulated in lung cancer ( Table 1) .
TUMOR SUPPRESSOR miRNAs AND ONCOGENIC miRNAs
In Table 1 , two out of 8 lung cancer reports show the miRNA expression profiles during embryonic lung and neonatal lung developmental process. There are four reports focusing on the dys-regulation of miRNAs from the normal lung to lung cancer, one report describes the different miRNA expression in the serum between lung cancer patients and healthy population, while the last one enumerates the miRNAs that have been linked with the survival of lung cancer patients. The report, WO2007/081740 A2, in which miRNAs have been paid much attention, is also included herewith ( Table 1) . In order to analyze the potential activity of miRNAs in lung cancer, we defined that the miRNA, either up-regulated during lung development process, or downregulated from normal lung to lung tumor transition, either down-expressed in lung tumor patients' serum, or had protective roles in lung cancer patients, obtained 1 point for each report. In turn, the miRNA will be subtracted 1 point. Accordingly, the total scores of each miRNA or miRNA family are shown in Table 2 . The total scores of miRNAs at 3 or over include let -7, miR-15, -26, -29, -30, -126, and -142. These miRNAs are lower expression in lung cancer when compared with the normal lung, and an increase during embryonic and/or neonatal lung developmental process. Also, the expression of these miRNAs decreases in the serum of lung cancer patients. Among those miRNAs, let-7 family becomes the most famous, and its tumor suppressor activities have been demonstrated by several groups [See details below]. miR-15a, together with miR-16-1, locating at the FRAs in 13q14.3, were lost or down-regulated in cancer with a tumor suppressor function partly by targeting the BCL2 oncogene [59, 75, 76] . miR-26a possessed the ability to attenuate proliferation in MYC-dependent cells, and was one of the 20 most abundant in E11.5 lung [13, 77] . miRNA-29 family reverted aberrant methylation in lung cancer by targeting 3 -UTRs of DNA methyltransferases 3A and 3B [67] , whereas miR-148 repressed methyltransferases 3B gene expression through a region in its ORF [78] . miR-126 and miR-126* could inhibit cancer metastasis and invasiveness not only in lung cancer, but also in breast cancer and prostate cancer [69, [79] [80] [81] . miR-142 has been found to play an important role in both bronchoalveolar stem cell and bronchial squamous carcinogenesis [82, 68] . Among the scores of those miRNAs at 2, miR-16, -100, -101, -143, -145 and -331 have been identified to down-regulate in lung cancer, squamous cell carcinoma of tongue, prostate tumor, cervical cancer, colorectal neoplasia, B-cell malignancies, and breast cancer [83] [84] [85] [86] [87] [88] [89] . Besides targeting BCL-2, miR-16 induces cell cycle arrest in A549 cells by regulating multiple cell cycle genes, including CCND1, CCND3 ,CCNE1 and CDK6 [83] . In addition, miR-101 expression decreases during cancer progression, paralleling an increase in EZH2, a mammalian histone methyltransferase that contributes to the epigenetic silencing of target genes and that regulates the survival and metastasis of cancer cells [85] . The down-expression of miR-143 and miR-145 has a consistency in many types of cancer, including lung cancer, B-cell malignancies, colorectal neoplasia, ACTH-secreting pituitary tumors [55, [88] [89] [90] [91] .
Take together, these miRNAs play tumor suppressor roles through inhibiting tumor proliferation, repressing the activity of oncogenes, reverting aberrant methylation, regulating the invasiveness, disturbing endothelial cell activities. In light of these data, we suppose that miRNAs with high scores could be potential tumor suppressor genes. Interestingly, the most remarkably down-regulated miRNAs of smoke rat lung are among the miRNAs with score 1 ( Table  2 ) [92] . Thus, cigarette smoke may change miRNA expression, especially tumor suppressor miRNAs at an early phase. In fact, treatment of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a carcinogen present in tobacco products, reduced the expression of a number of miRNAs, such as miR-101, miR-126*, miR-34 and miR-199 [93] . NNK treatment in rats repressed miR-126* but induced CYP2A3 [95] [96] [97] [98] [99] . Human CYP1B1, a protein abundant in cancerous tissues, is post-transcriptionally regulated by miR-27b [100] . The oncogenic activity of miR-27a in MDA-MB-231 cells is due, in part, to suppression of ZBTB10 and Myt-1 [101] . Transfection of lung carcinoma cells line H1299 with miR-93 reduces TP53INP1, leading to cell cycle arrest and apoptosis [102] , while oncogenic potential of miR-106 has been found in human T-cell leukemias [103] , which contributes to tumor cell proliferation in part by regulating cell cycle progression (p21/CDKN1A), and by modulating checkpoint functions [104] . miR-128 expression could significantly reduced glioma cell proliferation in vitro and glioma xenograft growth in vivo, through inducing a decrease in the Bmi-1 oncogene expression [105] . miR-155 is another marked miRNA [For reviews, see 106], in both the cancer cell [107] [108] [109] and the stem cell [110] , even in Epstein-Barr virus infected cells [111] . miR-196, a miRNA encoded at three paralogous locations in the A, B, and C mammalian HOX clusters, has an extensive, and evolutionarily conserved complementarity to the messages of HOXB8, HOXC8, and HOXD8 [112] . Levels of miR-210 expression showed an inverse correlation with disease-free and overall survival in breast cancer [113] . Further studies demonstrated that it could modulate cancer cell, endothelial cell, and erythrocytic cells response to hypoxia [113] [114] [115] , whereas miR-214 induced cell survival and cisplatin resistance by targeting Pten (phosphatase and tensin homolog) in human ovarian cancer [116] . Many of miRNAs with score 2, also have been proved as potential oncogenes. miR -136, -191, -196 and -210 were also up-regulated in breast cancer [117] , and miR-28 was upregulated in renal cell carcinoma significantly [118] . High expression of miR-103, often together with miR-107, correlated with poor survival of cancer patients [119, 120] . miR-122, a liver specific miRNA, enhanced the colony formation efficiency of the HCV replicon and increased the steady-state level of HCV RNA in HEK-293 cells [121] , while miR-125b acted as an oncogene, contributing to the pathogenesis of prostate cancer [122] . An increase in miR-127 expression was significantly associated with lymph node metastasis in cervical carcinomas [123] . The colon cancer patients with higher miR-200c expression had a shorter survival timing when compared to the patients with lower expression [124] . Moreover, the miR-200 family also determined the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2.
But these are not always the cases. miR-199 (Score -3) family members have demonstrated down-regulation in lung development and up-regulation in tumor in two reports. MiR199a showed down-regulation in NNK treated lung, but miR-199a * presented as a tumor suppressor gene, regulating the MET proto-oncogene and the downstream extracellular signal-regulated kinase 2 (ERK2) [93, 123, 125] . Moreover, miR-34 family (Score=0) has been found to join the p53 network [126, 127] . The expression of miR-34a, -34b, and34c is robustly induced by DNA damage and oncogenic stress in a p53-dependent manner. Tumor-suppressive miR-34 has been studied by several groups, but their linking with p53 still remains for further investigation.
miRNAs AS LUNG TUMOR SUPPRESSOR GENES-LET-7 FAMILY
let-7, as a tumor suppressor gene, might provide a prospective therapeutic strategy for the curing of lung cancer. let-7 is selected to study in details due to that (1) let-7 is the second miRNA identified; (2) It is the first miRNA found to be down-regulated in lung cancer; and (3) It is one of miRNAs well-studied. Till now, 154 pre-let-7 family members have been identified, including 11 in humans, hsa-let-7a-1, -7a-2, -7a-3, -7b, -7c, -7d, -7e, -7f-1, -7f-2, -7g, and -7i (Table 3), that finally generate 8 mature let-7 miRNAs with the same seed sequence(GAGGUA). Another miRNA, miR-98, being the same seed sequence, might also be included in let-7 family. Frequently, there was a decrease in the let-7 expression levels in lung cancer for both in vitro and in vivo [71, 72, 128] , but only a sporadic decrease in let-7 in breast and colon cancer samples. Northern analysis showed that the down-regulation of let-7c could change from 25 to 75%, and let-7g had an average 30% less expression in the lung tumor samples [128] . The down-regulation of let-7 has been associated with poor survival of lung patients [55, 71] . Moreover, work has been mapped let-7 family members to human chromosomal sites implicated in a variety of cancer [60] . let7a-2, let-7c and let-7g, in particular, have been linked to small chromosomal intervals which are deleted in lung cancers. These studies together showed that let-7 may have potential function in lung tumorigenesis. let-7 family may take effect through paring with 3'UTR of the targeting mRNAs. The first group as a target by let-7 is Ras genes (K-ras, N-ras and H-ras). The 3'UTR of the human Ras genes contains multiple let-7 complementary sites (LCSs) (Fig. 2) , allowing let-7 to regulate Ras expression [128, 129] . Fig. (2) . Let-7 complementary sites (LCSs) in 3'UTR of ras family and Hmga2 mRNA. Note: Only N-ras gene, but not K-ras and H-ras, has a LCS in its 3'UTR by using TargetScan and miRndna analysis, while Hmga2 has 7 conserved LCSs in its 3'UTR. The combined observations have revealed that (1) There is a decrease in let-7 expression in lung cancer; (2) Several let-7 genes map to genomic patients; (3) Over-expression of let-7 can inhibit lung tumor cell line growth; (4) The expression of the Ras oncogene is regulated by let-7, and (5 Significant over-expression of RAS in the lung tumor samples strongly implicates that let-7 is a tumor suppressor in the lung tissue [128] . Indeed, over-expression of let-7 in A549 lung adenocarcinoma cell line inhibited lung cancer cell growth in vitro. This discovery firstly indicated that let-7 may have potential clinical value in treating lung cancers [71] . Further studies reconfirmed that the let-7 miRNA could directly represses cancer growth in multiple lung cancer cell lines in vitro, as well as lung cancer cell xenografts in immunodeficient mice. Ectopic expression of let-7g in KRas G12D -expressing murine lung cancer cells induced both cell cycle arrest and cell death [130] , and inhibiting let-7 function, led to increase cell division in A549 lung cancer cells. Over-expression of let-7 in the cancer cell lines altered cell cycle progression and reduced cell division [14] . let-7 could also be applied as an intranasal drug to reduce tumor formation in a Ras mouse model lung cancer [131] . Besides acting as tumor suppressor directly, let-7 may also be a viable tool to augment current cancer therapies. Overexpression of let-7 in lung cancer cells could suppress radioresistance in those cells [132] . Nevertheless, reexpressing ectopic K-Ras G12D led to substantial, but not complete rescue of tumor growth in the face of elevated let-7g levels, suggesting that let-7 could suppress tumor growth by silencing more than one target.
Hmga2, which expressed a high-mobility protein, was also targeted by let-7 and the expression was inversely associated with survival [133, 134] . Similarly, ectopic expression of let-7 reduced HMGA2 and cell proliferation in a lung cancer cell [135] . The effect of let-7 on Hmga2 was also dependent on multiple LCSs in the 3' UTR. The growthsuppressive effect of let-7 on lung cancer cells was rescued by over-expression of the Hmga2 ORF without a 3'UTR [135] . However, in the case of expressing ectopic Hmga2, there was a less robust rescue of tumor growth when compared with re-expressing of K-Ras G12D [130] . It may be due to that the expression of Hmga2 represents an early event during cancer progression. Enforced let-7 expression has been found to be associated with a decrease in self-renewal in breast tumor-initiating cells and mouse mammary epithelial progenitor cells [136, 137] . An increase of let-7 in breast tumor-initiating cells was paralleled with a decrease of H-RAS and HMGA2. However, silencing H-Ras resulted in a decline in self renewal but causes no effect on differentiation, while silencing Hmga2 enhanced differentiation but produces no effect on self renewal [137] .
Hmga2 was more efficiently targeted by let-7 than Ras in NCI60 cell lines. Expression of Ras did not change when amounts of let-7 efficiently silences expression of Hmga2 in the tumor cells [138] . Indeed, using TargetScan, and miRndna, the two famous miRNA target prediction softwares (http://www.targetscan.org/index.html; http://www. microrna.org/microrna/ home.do), we did not found any LCS in K-ras and H-ras. One and 7 conserved LCSs were found in N-ras and Hmga2 3'UTR, respectively (Fig. 2) . However, over-expression of let-7a could indeed suppress N-ras, K-ras and H-ras [128, 130, 137] . Both TargetScan and miRndna predict biological targets of miRNAs mostly by searching for the presence of conserved sites that match the seed region of each miRNA. Nevertheless, a seed site is neither necessary nor sufficient for miRNA down-regulation. miRNA target sites can tolerate G:U wobble base pairs within the seed region. The extensive base pairing between the 3'UTR and the remainder of the miRNA may offset missing complementarity of the 5' seed [139] . Multiple target sites in the same 3'UTR can potentially increase the degree of translational suppression, thus the degree of repression corresponded to the number of intact sites [140] . Among the seven LCSs at 3'UTR of Hmga2, Lee and Dutta showed that LCS2541 did not respond to let-7 [135] , while Shell et al. found both LCS2521 and LCS2541 were targets for let-7, and targeting these two LCSs was sufficient to suppress expression of HMGA2 [141] . Except for let-7, K-ras and Hmga2 3'UTR have other potential targets for miRNAs, such as miR-155, 143 and -30. It still remains unclear whether these miRNAs can really regulate Ras and Hmga families, and whether they can cooperate with let-7 or not.
It is reported that let-7 negatively regulates expression of MYC directly by targeting their mRNAs for translation repression [128, 142] . However, inhibition of MYC-MAX transcription factor results in an increase in levels of members of the let-7 family (let-7a, let-7b, and miR-98) [142] . IMP-1, having growth-promoting activities through stabilization of c-Myc mRNA, is also a direct let-7 target [143] . let-7 also up-regulates MXI1, a transcription regulator which antagonizes MYC function [14] . These findings with let-7 family add to the complexity of MYC regulation, implying that dysregulation of these miRNAs may participate in the genesis and maintenance of cancer phenotype in MYCdysregulated cancers [142] .
Multiple genes involved in cell cycle and cell division functions are also directly or indirectly repressed by let-7 in both A549 lung cancer cells and HepG2 hepatic cancer cells, including CCNA2, CDC34, ASK/DBF4, AURKA/STK6, AURKB/STK12, E2F5, CDK8, PLAGL1 and PLAGL2 [14] . Combination with microarray analysis and miRNA predication program, PicTar, the putative genes targeted by let-7 include CDK6, PLAGL2, 2-PDE, CDC25A, DZIP1, OPRS1, DLC1, NXT2, E2F6, GPX7, SSR1,YAP1, ZNF336, SOX9, RRM2, STK6, FARP1, CBFB, DSCR1, CDCA7, MAP3K7IP2, GTF2I/GTF2IP1, ARID3A, DMD, CCNF, CCNJ, EIF2C3, CDC34, E2F5 and LIN28 [14] . CDK4, CDK6, CDC25A, CCND1, CCND3 and CCNA, have been identified as let-7 targets by 3'UTR reporter assays [14, 144] .
Besides direct anti-cancer activities, let-7 may also have functions related with angiogenesis. The mature form of let-7 miRNA was readily detectable in immortalized lung epithelial cell lines at a level comparable with that in the normal lung tissues [71] . Against let-7f reduced sprout formation, indicating that let-7f promote angiogenesis by targeting antiangiogenic genes, may be thrombospondin-1, and endogenous angiogenesis inhibitor [145] . In addition, let-7 is down-regulated in mouse mammary epithelial progenitor cells [136] . However, it remains to be ascertained whether such a function could suppress tumor growth or not?
Recently, researches about epigenetics of let-7 gene impels to pay more attention to the potential therapy function of those family. Several reports showed that the human let-7a-3 gene on chromosome 22q13.31 was associated with a CpG island, and it was heavily methylated in normal human tissues and hypomethylated in some lung adenocarcinomas. let7a-3 hypomethylation facilitated epigenetic reactivation of the gene and elevated expression of let-7a-3 in a human lung cancer cell line resulted in enhanced tumor phenotypes and oncogenic changes in transcription profiles [146] . Ovarian cancer patients with methylated let-7a-3 seemed to reduce risk from death compared with those without, and the association was independent of patient's age at surgery, tumor grade, disease stage, and IGF-II or IGFBP-3 expression, but the expression of let-7a was slightly affected by the methylation [147] . In addition, let-7a-2 and let-7g were found upregulated in Volinia's reports [53] . And the serum level of let-7b, let-7c, let-7d and let-7e increased in lung cancer patients compared with healthy [65] . Therefore, the individual function of the let-7 family members requires further investigation. Indeed, we found that mature let-7 members had different ability to suppress A549 cell growth in our recently in vitro study (see Fig. 3, n=6) . let-7i was the highest repression effect, while let-7d and let-7e had a little least repression when compared with other let-7 family. The similar phenomenon was found by Johnson and colleagues [14] . Another question is whether let-7 would repress tumorsuppressor genes which append the Hmga2 3' UTR. Hmga2 translocations frequently append the Hmga2 3' UTR to the 3' end of known tumor-suppressor genes, including FHIT, RAD51L1, or HEI10. Repression of these translocation partners with let-7 might cooperate with Hmga2 to promote tumorigenesis [140] .
miRNAs AS ONCOGENES-miR-17-92 CLUSTER
In the miR-17-92 cluster, containing the miR- 17-18-19-20-92 and residing in intron 3 of the C13orf25 gene at 13q31.3 (within a 800bp region), the up-regulation in lymphoma cell lines was first discovered (Fig. 4) [63] . miR-17-92 cluster was markedly over-expressed in lung cancers, especially with SCLC histology [148] . However, overexpression of the C13orf25 ORF did not enhance lung cancer cell growth. Furthermore, the vast majority of C13orf25 transcripts were detected as Drosha-processed cleavage products [149, 150] . Thus, the C13orf25 gene may only be serving as a vehicle for miR-17-92 expression. Indeed, a novel polyadenylation site is present 3' to the miR-17-92 cluster, and 5' to the C2 region (C2 region is resided 3' to miR-17-92 in the intron 3 of C13orf25) [150] . Enforced expression of C2 led to a marked tumor growth inhibition in association with double stranded RNA-dependent protein kinase activation. Supporting evidences came from a direct experiment that the miR-17-92 cluster had oncogenic activity [149] . In the lung cancer cell lines, SK-LC-2 and Calu6 exhibited a marked increase in gene copy numbers of miR-17-92 cluster, while ACC-LC-94, PC-1, PC-10, ACC-LC-97 and ACC-LC-76 showed a moderate increase in copy number. An increase in expression of miR-20 in vivo was observed in all five primary SCLC specimens. The observation revealed that the expression of the miR-17-92 cluster could enhance lung cancer cell growth [148] . Linkage between the miR-17-92 cluster and the Myc oncogenes has been proposed [151] , and concomitant Myc and miR-17-92 cluster amplification has been discovered in multiple human cancers including lung cancer [148, [151] [152] [153] [154] . The transcription of the miR-17-92 cluster was directly up-regulated by C-MYC [151, 154, 155] , in contrast, inhibition of MYC-MAX transcription factor with 10058-F4 reduced the level of miR-17-5p [142] . The members of the Myc gene family (c-Myc, lMyc and n-Myc) have been shown to be frequently amplified and/or over-expressed in SCLC [148] . It has been shown that E -Myc mice enforced by over-expression of the miR- 17-19b , could develop tumor significantly earlier than those without expression [149] . Furthermore, the miR-17-92 cluster and C-MYC could synergistically contribute to cancer development [154] . Up-regulation of miR-17-92 cluster and c-Myc might contribute to tumorigenesis via the downregulation of both the TßRII-Smads and the C-MYC-Miz-1-p15
INK4b pathways, respectively [154] . In the lung, n-Myc is specifically expressed in the epithelium, while c-Myc is transcribed only in the mesenchyme. Over-expression of n-Myc in the lung epithelium under the control of human Sftpc regulatory elements, cause elevated cell proliferation and inhibition of differentiation, with a phenotype very similar to the phenotype of miR-17-92 cluster transgenic mice. At least, it has been postulated that high level of the miR-17-92 cluster might negatively regulate n-Myc expression [45] .
In addition, both thrombospondin-1 (Tsp1) (targeted by miR-19) and connective tissue growth factor (CTGF) (targeted by miR-18) are predicted targets for repression by the miR-17-92 cluster [155] . The angiogenic activity of C-MYC is partly due to downstream activation of the miR-17-92 that has down-regulated those antiangiogenic proteins. The transcription factor E2F1 is a target of two of the miRNAs encoded by miR- 17-92(miR-17-5p and -20a) , and the gene encoding E2F1 is also a target of C-MYC [151, 156] . The correlation between E2Fs mRNA and the expression of the miR-17-92 cluster is reconfirmed by two other groups [157, 158] . All 3'UTR of E2F1, E2F2 and E2F3 mRNA have miR-20a binding sites [157] . The core promoter region of miR-17-92 cluster gene contains two functional E2F transcription factor binding sites. E2F3 is the primary E2F fam- ily member that occupies the promoter [156, 158] . E2F1, E2F2, and E2F3 can directly activate transcription of miR-17-92 by binding the promoters [158] , and their effects similarly [157] . However, miR-20a that reduced E2F1 expression is more significant than E2F2 and E2F3 [157] . The negative feedback loop established between transcription factor and miR-17-92 may shift the E2F transcriptional balance away from the pro-apoptotic E2F1 and toward the proliferative E2F3 transcriptional network [158] . Such a balance shift may be also contributed by MYC, which could transactivate E2Fs. E2Fs, Myc and miR-17-92 cluster together provide a complex regulatory for cell proliferation and/or apoptosis.
Other targets of miR-17-92 cluster include both oncogenes and antiapoptotic genes (Ncoa3, targeted by miR-17-5p) and tumor suppress genes or proapoptotic genes (Pten, targeted by miR-19; Rbl2, targeted by miR-17-5p; Bim, targeted by miR- [153, [159] [160] [161] . Among them, BIM, a proapoptotic protein that regulated cell death, has been confirmed that it was up-regulated in the lungs of miR-17-92 null late gestation embryos [162] , and Rbl2 was a direct target of miR-17-5p during normal lung development. It is still unknown that other genes are directly targeted by miR- or not and whether their relationship would be functional in lung development and lung cancer. Nevertheless, significant distinctions among miRNAs of the miR-17-92 cluster have been found, just as above enumerated, in terms of their roles in cancer cell growth. For example, mature miR-19a has a very low abundance when compared with other members, while miR - 17-5p, -20a, and -19b are present in both the epithelium and mesenchyme of the embryonic lung [13] . Inhibition of miR-17and miR-20a with antisense oligonucleotides could induce apoptosis selectively in lung cancer cells by over-expressing miR-17-92 [150] . In contrast, antisense oligonucleotides against miR-18a and miR-19a do not exhibit such inhibitory effects, whereas inhibition of miR-92-1 results in only modest reduction of cell growth.
In addition to its up-regulation in cancer cells, miR-17-92 is highly expressed in embryonic stem cells, with a decrease in expression levels during embryonic development in mice [13] . Expression of the miR-17-92 cluster is considerablely high at early stages, but declines as lung development proceeds [45] . Transgenic over-expression of the miR-17-92 cluster by mouse surfactant protein C promoter promotes the high proliferation and undifferentiated phenotype of lung epithelial progenitor cells, and transgenic lungs have a very abnormal lethal phenotype [45] . Interestingly, deletion of miR-17-92 leads to severely hypoplastic lungs [162] . These findings clearly suggest that marked over-expression of the miR-17-92 cluster with occasional gene amplification may play a role in the development of lung cancers. Also, taken together, the present findings contribute towards better understanding of the oncogenic roles of miR-17-92, which might ultimately lead to the future translation into clinical applications.
miRNA BIOGENESIS AND LUNG CANCER
Differential miRNA expression has been described in lung and lung cancer as above, both in mouse and humans. But only one Dcr gene exists in the mouse and human genome, which presumably mediates the processing of all miRNAs and endogenous siRNAs. Several mutant alleles of Dcr have been generated in mouse, and analyses of their phenotypes demonstrate that Dcr functions in multiple developing tissues [163] [164] [165] [166] [167] [168] [169] . Dcr plays a specific role in regulating lung epithelial morphogenesis independent of its requirement in cell survival [170] . Dcr mutant lungs exhibit two major cellular defects: first, a disruption in epithelial morphogenesis and second an increase in epithelial cell death. In the mesenchyme of Dcr mutant lungs, the expression of Fgf10, a key gene involved in lung development, was found up-regulated and expanded. However, the mechanism by which DCR functions in the epithelium to influence Fgf10 expression in the mesenchyme remains unclear [170] . It has been reported that Ago2-null mice die early in development, and show severe neural tube defects [171] . The embryo analysis of day 11.5 and 14.5 is expressed, which is the member of ago gene family, the analysis in includes the brain, neural tube, limb, lungs, and hair follicles. In the developing lung, expression of Ago1 and Ago2 is localized to branching regions, in distal epithelium and mesenchyme, respectively. These are sites undergoing the most dynamic changes in gene expression and rapid remodeling [50] .
In the multistep carcinogenesis model, peripheral adenocarcinoma of the lung develops from noninvasive precursor lesions known as atypical adenomatous hyperplasia (AAH) and BAC. The stoichiometry of miRNA machinery and RISC depends on histologic subtype of lung carcinoma, varies along the AAH-BAC-adenocarcinoma sequence. DCR is up-regulated in AAH and BAC and down-regulated in areas of invasion and in advanced adenocarcinoma [172] . Higher DCR level in SCLC is found when compared with adenocarcinoma. Other proteins of the RNA-induced silencing complex (RISC, SND1, PACT, and FXR1) and are also present at higher levels in a SCLC cell line when compared with an adenocarcinoma cell line. In 67 NSCLC cases, DCR expression levels are reduced in a fraction of lung cancers with a significant prognostic impact on the survival of surgically treated cases [173] . DCR expression is inversely correlated with expression levels of mature let-7 in a panel of human cancer cell lines. Over-expression of let-7 significantly reduces the expression of DCR at both the protein and mRNA levels, whereas reduction of let-7 expression conversely increases DCR at both levels. There is possible existence of a novel regulatory loop, in which let-7 may play a role as a key miRNA for implementing the tightly regulated, equilibrated state of DCR and various miRNAs [174] .
Conditional deletion of Dcr enhances tumor development in a K-Ras-induced mouse model of lung cancer [175] . Cancer cells expressing siRNAs which target three different components of the miRNA processing machinery, show a substantial decrease in steady-state miRNA levels and a more pronounced transformed phenotype [175] . These results indicate the involvement of reduced DCR expression in the development of lung cancers. The up-regulation of DCR has also been observed in prostatic intraepithelial neoplasia, and in 81% of prostate adenocarcinoma [176] . However, the underlying mechanisms are still unclear. Loss of LOH on the long arm of chromosome 14, where Dcr resides, has been reported in lung cancers [177, 178] , therefore the altered chromatin conformation and haploinsufficiency may be a possible explanation. Since Dcr is one of targets by let-7 family, therefore down-regulation of let-7 in lung cancer may promote tumorigenesis through up-regulation with DCR.
PROSPECTIVE AND CONCLUSION
miRNAs are frequently dysregulated in lung cancer and have shown to be a promise as tissue-based markers for cancer classification and prognostication. The 1st validated miRNA diagnostic assay developed by Asuragen has been used to improve diagnostics in pancreatic cancer. The finding that miRNAs originated from lung cancer are present in human plasma in a remarkably stable form, supports them to serve as useful clinical biomarkers, for blood-based detection of human cancer and other diseases in particular.
It is important for that some miRNAs function as oncogenes while others act as tumor suppressors in pharmaceutical industry. For oncogenic miRNAs, miRNA inhibitors with single stranded PNA probe could be used to specifically inhibit each of endogenous miRNAs individually. As for tumor suppression miRNAs, such as let-7 family, a desirable therapeutic strategy, enhance their functions in cells. The feasibility of miRNA-based therapeutics has been well supported by data from preclinical models and ongoing clinical trials. For example, antisense oligonucleotides corresponding to miR-17and miR-20a could specifically induce apoptosis in lung cancer cells over-expressing miR-17-92 [150] . And chemically modified cholesterol-conjugated single strand RNA complementary to a mature miRNA, or called "antagomir", has been reported which could markedly inhibit miRNA expression and function [69] . let-7 over-expressing by viral vector or transfected directly by pre-miRNAs could inhibit lung cancer growth both in vitro and in vivo. Encouragingly, the first miRNA drug, SPC3649, has been used for hepatitis C infection therapy.
Potential targeting genes in lung cancer for miRNAbased RNAi includes oncogenes (e.g. Ras family, Myc family), autocrine/paracrine loops (e.g. EGBB family, IGF axes), anti-apoptotic genes (e.g. BCL-2 family, XIAP), genes that promote tumor vasculature development (e.g. VEGF family, VEGFR family), MMP family, cell circle related genes(e.g. Skp-2, Cyclin family, Cdk family), and metastasis related genes (e.g. E-cadherin, COX2), chemoresistance genes (e.g. FGF family, GSTP1), and other genes (e.g. CT120A, DDH). In lung cancer, these genes targeted by artificial siRNAs have been partly studied [179] . And drug base-siRNAs has entered phase I/II trails and showed with good potential (e.g. ALN-RSV01, Cand5, Sirna-027) [180] . This oligo-based therapeutics should facilitate miRNAs to clinical use for their high comparability. The advantages of using miRNAs over siRNAs may be because of (1) long-term activity, (2) in vivo stability, (3) highly RNA promoter-compatibility and (4) no overt toxicity. Nevertheless, miRNAs are of multiple targets when compared with siRNAs. Balance and caution must be taken into consideration, as the systemic delivery of miRNA may lead to unwanted gene silence. An investigation on all possible targets and potential effects must be carried throughout prior to the initiation of any clinical trail. The potential of miRNAs in facilitating diagnosis, prognosis, and survival outcome for lung cancer should also be made feasible. 
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